All In Biotech

Drug Trial Radar · NCT05869955

A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)

A Phase 1, Multicenter, Open-Label Study Of CC-97540 (BMS-986353), CD19-Targeted Nex-T Chimeric Antigen Receptor (CAR) T Cells, in Participants With Severe, Refractory Autoimmune Diseases: Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy, Systemic Sclerosis, or Rheumatoid Arthritis (Breakfree-1)

Last checked: Nov 20, 2026Latest source record: Aug 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

270

Planned (sponsor's estimate)

Start

Sep 13, 2023

Primary completion

Aug 29, 2028

Study completion Aug 29, 2028

Sponsor

Lead sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyBristol Myers Squibb (BMY)
Sponsor type
Industry
Collaborators
Bristol-Myers Squibb Services Unlimited Company
First posted
May 23, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to establish the tolerability, preliminary efficacy, and pharmacokinetics of CC-97540 in participants with severe, refractory autoimmune diseases (Breakfree-1).

Conditions

  • Systemic Lupus Erythematosus
  • Idiopathic Inflammatory Myopathy
  • Systemic Sclerosis
  • Rheumatoid Arthritis

Interventions

  • CC-97540Drug

    Specified dose on specified days

  • FludarabineDrug

    Specified dose on specified days

  • CyclophosphamideDrug

    Specified dose on specified days

  • TocilizumabDrug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with treatment-emergent adverse events (AEs) in each indication.Time frame: Up to 2 years after CC-97540 infusion
  2. Number of participants with serious AEs (SAEs) in each indication.Time frame: Up to 2 years after CC-97540 infusion
  3. Number of participants with AEs of special interest (AESI) in each indication.Time frame: Up to 2 years after CC-97540 infusion
  4. Number of participants with laboratory abnormalities in each indication.Time frame: Up to 2 years after CC-97540 infusion
  5. Number of participants with Dose Limiting Toxicities (DLT) in each indication.Time frame: Up to 2 years after CC-97540 infusion
  6. Recommended Phase 2 Dose (RP2D) of CC-97540 in each indication.Time frame: Up to 2 years after CC-97540 infusion

Locations

46 sites in 6 countries. Site status is shown where the registry gives one.

  • Local Institution - 0035

    Aurora, Colorado

  • Local Institution - 0024

    Denver, Colorado

  • Local Institution - 0006

    Jacksonville, Florida

  • Local Institution - 0056

    Miami, Florida

  • Local Institution - 0053

    Chicago, Illinois

  • Local Institution - 0038

    Boston, Massachusetts

  • Local Institution - 0033

    Worcester, Massachusetts

  • University of Massachusetts Chan Medical School

    Worcester, Massachusetts

  • Local Institution - 0031

    Ann Arbor, Michigan

  • Local Institution - 0037

    Detroit, Michigan

  • Local Institution - 0022

    Rochester, Minnesota

  • Local Institution - 0010

    St Louis, Missouri

  • Local Institution - 0028

    Omaha, Nebraska

  • Local Institution - 0008

    Summit, New Jersey

  • Local Institution - 0002

    New York, New York

  • Local Institution - 0011

    New York, New York

  • Local Institution - 0007

    New York, New York

  • Local Institution - 0003

    Chapel Hill, North Carolina

  • Local Institution - 0005

    Cleveland, Ohio

  • Local Institution - 0036

    Dallas, Texas

  • Local Institution - 0029

    Houston, Texas

  • Local Institution - 0034

    Houston, Texas

  • Local Institution - 0004

    Seattle, Washington

  • Local Institution - 0057

    Seattle, Washington

  • Local Institution - 0058

    Seattle, Washington

  • Local Institution - 0019

    Leuven, Vlaams-Brabant, Belgium

  • Local Institution - 0016

    Lille, France

  • Local Institution - 0040

    Nice, France

  • Local Institution - 0018

    Paris, France

  • Local Institution - 0020

    Rennes, France

  • Local Institution - 0044

    Pessac, Aquitaine, France

  • Local Institution - 0015

    Montpellier, Hérault, France

  • Local Institution - 0025

    Berlin, Germany

  • Local Institution - 0047

    Düsseldorf, Germany

  • Local Institution - 0017

    Erlangen, Germany

  • Local Institution - 0049

    Würzburg, Bavaria, Germany

  • Local Institution - 0042

    Cologne, North Rhine-Westphalia, Germany

  • Local Institution - 0041

    Leipzig, Saxony, Germany

  • Local Institution - 0045

    Magdeburg, Saxony-Anhalt, Germany

  • Local Institution - 0012

    Rome, Lazio, Italy

Showing 40 of 46 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.